Medytox files new lawsuits against Daewoong Pharmaceutical in the United States

Medytox Inc. said Monday it has filed two new lawsuits against Daewoong Co., Daewoong Pharmaceutical Co., and Daewoong Pharmaceutical’s U.S. partner AEON Biopharma Inc., starting a new legal fight with its Korean botox competitor after a tripartite settlement involving Medytox , its American partner Allergan and the American partner of Daewoong Evolus in the field of cosmetic use after the decision of the US International Trade Commission (ITC).

AEON is the licensee of Daewoong Pharmaceutical for the right to approve, import and distribute Daewoong’s botulinum toxin product Nabota for therapeutic purposes in the United States, Europe and Canada.

Medytox’s lawsuit against Daewoong Pharmaceutical and AEON filed in California claims the two companies are still trying to sell products made by stealing trade secrets related to its strain of botox and manufacturing process despite ITC’s final ruling who promoted Medytox.

Daewoong Pharmaceutical resumed sales of Nabota in the US market after the ITC withdrew its 21-month import ban after accepting Medytox’s request under the tripartite settlement agreement.

Another new lawsuit filed by Medytox in Virginia against Daewoong and Daewoong Pharmaceutical argues that the two have obtained US patents for the production of botox based on stolen trade secrets.

By Pulse

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]